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Abstract
Influenza viruses are classified based on their surface 
glycoproteins: hemagglutinin and neuraminidase.  
Hemagglutinin (HA) is responsible for binding to the host cell, 
while neuraminidase (NA) facilitates escape of newly formed 
virus particles. These studies determined the NA activity of three 
subtypes of influenza A virus that differ in their ability to cause 
disease in mice:  influenza A/NWS/33 (H1N1), influenza A/
Victoria/3/75 (H3N2), and influenza A/Duck/MN/1525/81 
(H5N1).  Chemiluminescent quantitation of NA activity in equal 
amounts of each virus was determined in three replicate 
experiments.  Results indicate that N1 virus subtypes have 
higher NA activity than do N2 subtypes.  In addition, the NA 
activity of each virus was tested in the presence of the NA 
inhibitor oseltamivir.  Effective antiviral concentrations of 
oseltamivir for each virus were EC50 = 0.51, 0.19, and 0.70 nM 
for NWS, Victoria, and Duck viruses, respectively.  These results 
do not support the hypothesis that NA activity alone determines 
the ability of the virus to cause disease. However, these data do 
suggest a correlation between NA activity and virus resistance to 
oseltamivir.
Introduction
Neuraminidase activity is critical for the virus to release itself 
from infected cells [1].  This in turn will cause subsequent virus 
spread.  NA has also been proposed to aid in the entry of the 
virus into target cells [2].  This occurs during the initial stages of 
infection.  The roles of NA in influenza are important for its 
success and ability to cause disease.  A focus of current 
chemotherapeutic treatment regimens involve inhibiting the 
activity of the NA enzyme.  These antiviral drugs are called 
neuraminidase inhibitors.  Oseltamivir, zanamivir, and peramivir 
are used and studied today.  Influenza has shown an incredible 
increase of resistance to oseltamivir.  In the 2007 - 2008 winter, 
the virus tested positive for resistance 11% of the time from 
throat swabs of patients with the most common influenza 
subtype [3].  Since then, the resistance of the virus has been 
increasing.
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Conclusions
These studies conclude that NA subtype one (N1) has a higher 
NA activity comparative to NA subtype two (N2).  The Duck 
virus is most resistant to oseltamivir in the NA-Star® assay and 
in cell culture studies.  These data suggest there is correlation 
between NA activity and virus resistance to oseltamivir.  This 
research will hopefully lead to better ways of identifying drug-
resistant influenza virus strains.
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Effective Concentration of Oseltamivir
Influenza Subtype
Visual Neutral Red
EC50 (µM) CC50 (µM) SI EC50 (µM) CC50 (µM) SI
NWS (H1N1) 0.141±0.045 >32 >256±110 17.2±13.6 >32 >5.28±7.72
Victoria (H3N2) 0.090±0.038 >32 >407±128 10.76±11.5 >32 >4.23±4.17
Duck (H5N1) 4.67±1.12 >32 >7.2±1.99 8.80±3.17 >32 >4.3±2.40
Figure 3: 
Neuraminidase 
activity graphed as 
percent 
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vs oseltamivir 
concentration in nM.
Figure 1: A model of the influenza virus [5].
Figure 4: In Vitro Testing Results in MDCK cells
Methods
Virus subtypes and the NA inhibitor, Oseltamivir, were provided 
by the Institute for Antiviral Research.  The virus stocks used 
were Influenza A/NWS/33 (H1N1), influenza A/Victoria/3/75 
(H3N2), and influenza A/Duck/MN/1525/81 (H5N1).  In each 
test, virus subtypes were used at equal titers and run in triplicate.
The effect of oseltamivir on viral neuraminidase activity was 
performed using a commercially available kit (NA-Star® 
Influenza Neuraminidase Inhibitor Resistance Detection Kit, 
Applied Biosystems, Foster City, CA) in 96-well solid white 
microplates following the manufacturer’s instructions [4,6].  
Oseltamivir in half-log dilution increments was incubated with 
virus (as the source of neuraminidase).  The amount of virus in 
each microwell was approximately 500 cell culture infectious 
doses (CCID50).  Plates were pre-incubated for 20 minutes at 
37oC prior to addition of chemiluminescent substrate.  Following 
addition of substrate plates were incubated for 30 minutes at 
37oC.  The neuraminidase activity was evaluated using a Centro 
LB 960 luminometer (Berthold Technologies) for 0.5 seconds 
immediately after addition of NA-Star® accelerator solution.  
Fifty percent virus-inhibitory concentrations (EC50 values) of 
viral neuraminidase activity were determined by plotting percent 
chemiluminescent counts versus log10 of oseltamivir 
concentration.  NA activity of each virus subtype was determined 
by completing the assay using only buffer.
Antiviral activity of oseltamivir carboxylate, the active form of 
oseltamivir, was determined in Madin-Darby canine kidney 
(MDCK) cells.  The cells were grown in MEM supplemented 
with 5% FBS.  The assays were completed in 96-well 
microplates infected with approximately 50 CCID50 of virus.  
Microplates were visually examined after 3 days of infection and 
then treated for 1.5 hours with neutral red (0.011% final 
concentration) to quantify the virus-induced cytopathic effects 
(CPE).  Excess dye was rinsed from cells with PBS.  The 
absorbed dye was eluted from the cells by addition of 0.1 ml of 
50% Sorensen’s citrate buffer/50% ethanol to each well.  Optical 
density (OD) measurements were completed on the microtiter 
plates at 560 nm.  OD readings were converted to percent of 
uninfected control using an Excel spread sheet developed for this 
purpose.  EC50 values were determined by plotting percent CPE 
versus log10 of inhibitor concentration.
Figure 2: 
Neuraminidase activity 
of each virus subtype 
tested at equal virus 
concentrations.
Shown by Figure 2, NA activity levels at equal concentrations of 
virus indicate that the N1 subtype has a higher NA activity than 
does the N2 subtype.  Additional testing of several other 
influenza virus subtypes have corroborated these data.
Figure 3 shows the dose-response curve of each of the viruses in 
the presence of oseltamivir.  Effective concentration values of 
oseltamivir for each virus subtype were EC50 = 0.51, 0.19, and 
0.70 nM for NWS, Victoria, and Duck viruses, respectively.  
These data indicate that the Duck virus is more resistant to 
oseltamivir than is the NWS or the Victoria viruses.  The NWS 
virus is more resistant than is the Victoria virus.  A virus 
expressing resistance is one that requires a higher concentration 
of oseltamivir to inhibit the NA activity. These data also indicate 
that a higher concentration of oseltamivir than was used in these 
assays would be required for complete inhibition of NA activity 
for the Duck virus.
Results shown in Figure 4 are the mean and standard deviation of 
four replicates of in vitro testing in MDCK cells.  The visual 
observation indicates that a higher concentration of oseltamivir is 
required to inhibit the Duck virus compared to the NWS virus 
and the Victoria virus.
Results
The virus titers were 1 x 10 4.8,  1 x 10 6.3,  and 1 x 10 6.4  PFU/ml 
for NWS, Victoria, and Duck viruses respectively.  Virus titers 
were equalized using dilutions.  The dilutions used were 1:5, 
1:90, and 1:90 for NWS, Victoria, and Duck viruses, respectively.
EC50 - Effective concentrations   CC50 - Cell cytotoxicity   SI - Selectivity Index (CC50/EC50)
